Financial giants have made a conspicuous bullish move on BioNTech. Our analysis of options history for BioNTech BNTX revealed 9 unusual trades.
Delving into the details, we found 66% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $474,356, and 2 were calls, valued at $61,360.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $82.5 to $190.0 for BioNTech over the recent three months.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for BioNTech's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across BioNTech's significant trades, within a strike price range of $82.5 to $190.0, over the past month.
BioNTech Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BNTX | PUT | SWEEP | BULLISH | 01/17/25 | $8.3 | $7.5 | $7.6 | $85.00 | $163.1K | 883 | 0 |
| BNTX | PUT | SWEEP | BULLISH | 08/16/24 | $4.5 | $4.0 | $4.0 | $85.00 | $85.3K | 0 | 0 |
| BNTX | PUT | SWEEP | BULLISH | 01/17/25 | $8.1 | $7.6 | $7.6 | $85.00 | $81.3K | 883 | 240 |
| BNTX | PUT | TRADE | BULLISH | 08/16/24 | $3.2 | $2.8 | $2.88 | $82.50 | $57.6K | 0 | 0 |
| BNTX | CALL | TRADE | BEARISH | 06/20/25 | $11.3 | $10.9 | $10.9 | $95.00 | $33.7K | 272 | 0 |
About BioNTech
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Following our analysis of the options activities associated with BioNTech, we pivot to a closer look at the company's own performance.
Current Position of BioNTech
- With a trading volume of 322,166, the price of BNTX is down by -1.57%, reaching $84.53.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 45 days from now.
Professional Analyst Ratings for BioNTech
In the last month, 5 experts released ratings on this stock with an average target price of $113.0.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $113.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $113.
- Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $113.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $113.
- An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $113.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for BioNTech, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
